| EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom MH Alava, A Wailoo, S Grimm, S Pudney, M Gomes, Z Sadique, D Meads, ... Value in health 21 (1), 49-56, 2018 | 95 | 2018 |
| The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment SE Grimm, M Strong, A Brennan, AJ Wailoo PharmacoEconomics 35 (12), 1287-1296, 2017 | 59 | 2017 |
| Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. M Westwood, B Ramaekers, S Lang, S Grimm, S Deshpande, S de Kock, ... Health Technology Assessment (Winchester, England) 22 (44), 1-264, 2018 | 48 | 2018 |
| Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models SE Grimm, X Pouwels, BLT Ramaekers, B Wijnen, S Knies, J Grutters, ... PharmacoEconomics 38 (2), 205-216, 2020 | 36 | 2020 |
| The use of real world data for the estimation of treatment effects in NICE decision making H Bell, A Wailoo, MH Alava, R Grieve, RIN De Faria, L Gibson, S Grimm NICE Decision Support Unit, 2016 | 34 | 2016 |
| High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. M Westwood, B Ramaekers, S Grimm, G Worthy, D Fayter, N Armstrong, ... Health Technology Assessment (Winchester, England) 25 (33), 1-276, 2021 | 29 | 2021 |
| Health technology assessment: a framework M Joore, S Grimm, A Boonen, M De Wit, F Guillemin, B Fautrel RMD open 6 (3), 2020 | 28 | 2020 |
| Framework for analysing risk in health technology assessments and its application to managed entry agreements S Grimm, M Strong, A Brennan, A Wailoo Sheffield: University of Sheffield, 2016 | 23 | 2016 |
| Assessing the expected value of research studies in reducing uncertainty and improving implementation dynamics SE Grimm, S Dixon, JW Stevens Medical Decision Making 37 (5), 523-533, 2017 | 22 | 2017 |
| Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review ME Westwood, N Armstrong, G Worthy, D Fayter, BLT Ramaekers, ... Clinical Chemistry 67 (1), 237-244, 2021 | 21 | 2021 |
| Cost assessment of health interventions and diseases B Fautrel, A Boonen, M de Wit, S Grimm, M Joore, F Guillemin RMD open 6 (3), e001287, 2020 | 21 | 2020 |
| Arsenic trioxide for treating acute promyelocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal BLT Ramaekers, R Riemsma, S Grimm, D Fayter, S Deshpande, ... Pharmacoeconomics 37 (7), 887-894, 2019 | 21 | 2019 |
| Cost-effectiveness of digital breast tomosynthesis in population-based breast cancer screening: a probabilistic sensitivity analysis VDV Sankatsing, K Juraniec, SE Grimm, MA Joore, RM Pijnappel, ... Radiology, 192505, 2020 | 18 | 2020 |
| EMA and NICE appraisal processes for cancer drugs: current status and uncertainties R Dickson, A Boland, R Duarte, E Kotas, N Woolacott, R Hodgson, ... Applied health economics and health policy 16 (4), 429-432, 2018 | 17 | 2018 |
| When future change matters: modeling future price and diffusion in health technology assessments of medical devices SE Grimm, S Dixon, JW Stevens Value in Health 19 (6), 720-726, 2016 | 16 | 2016 |
| Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal P Tappenden, C Carroll, JW Stevens, A Rawdin, S Grimm, M Clowes, ... PharmacoEconomics 35 (8), 805-815, 2017 | 15 | 2017 |
| Comparing the EQ-5D-3L and 5L versions A Wailoo, M Hernandez Alava, S Grimm, S Pudney, M Gomes, Z Sadique What are the implications for cost effectiveness estimates, 2017 | 13 | 2017 |
| Cannabidiol for adjuvant treatment of seizures associated with Lennox–Gastaut syndrome and Dravet syndrome: an evidence review group perspective of a NICE single technology … B Wijnen, N Armstrong, B Ramaekers, W Witlox, M Westwood, D Fayter, ... PharmacoEconomics 38 (10), 1043-1053, 2020 | 12 | 2020 |
| Estimating Future Health Technology Diffusion Using Expert Beliefs Calibrated to an Established Diffusion Model SE Grimm, JW Stevens, S Dixon Value in Health 21 (8), 944-950, 2018 | 12 | 2018 |
| Nivolumab for treating metastatic or unresectable urothelial cancer: an evidence review group perspective of a NICE single technology appraisal SE Grimm, N Armstrong, BLT Ramaekers, X Pouwels, S Lang, ... PharmacoEconomics 37 (5), 655-667, 2019 | 11 | 2019 |
Jos KleijnenRetired Professor of Systematic Reviews in Health Care, Maastricht University在 systematic-reviews.com 的电子邮件经过验证
